Search

Your search keyword '"Lai, Yongqing"' showing total 424 results
Start Over Author "Lai, Yongqing"
424 results on '"Lai, Yongqing"'

1. Numerical Study on the Bearing Mechanism of Hybrid Monopile-Bucket Foundations for Offshore Wind Turbines

Author

Lai, Yongqing, He, Ben, Li, Wei, Xiong, Gen, di Prisco, Marco, Series Editor, Chen, Sheng-Hong, Series Editor, Vayas, Ioannis, Series Editor, Kumar Shukla, Sanjay, Series Editor, Sharma, Anuj, Series Editor, Kumar, Nagesh, Series Editor, Wang, Chien Ming, Series Editor, Cui, Zhen-Dong, Series Editor, Ha-Minh, Cuong, editor, Pham, Cao Hung, editor, Vu, Hanh T. H., editor, and Huynh, Dat Vu Khoa, editor

Published
2024
Full Text
View/download PDF

5. Pile Shape Effects on the p-y Curves of Laterally Loaded Piles in Soft Clay

Author

Lai, Yongqing, Wang, Lizhong, Hong, Yi, Wang, Huan, di Prisco, Marco, Series Editor, Chen, Sheng-Hong, Series Editor, Vayas, Ioannis, Series Editor, Kumar Shukla, Sanjay, Series Editor, Sharma, Anuj, Series Editor, Kumar, Nagesh, Series Editor, Wang, Chien Ming, Series Editor, Huynh, Dat Vu Khoa, editor, Tang, Anh Minh, editor, Doan, Dinh Hong, editor, and Watson, Phil, editor

Published
2022
Full Text
View/download PDF

6. [Corrigendum] MicroRNA‑222‑3p promotes tumor cell migration and invasion and inhibits apoptosis, and is correlated with an unfavorable prognosis of patients with renal cell carcinoma

Author

Zhao, Liwen, primary, Quan, Jing, additional, Li, Zuwei, additional, Pan, Xiang, additional, Wang, Jingyao, additional, Xu, Jinling, additional, Xu, Weijie, additional, Guan, Xin, additional, Li, Hang, additional, Yang, Shangqi, additional, Gui, Yaoting, additional, Chen, Yun, additional, and Lai, Yongqing, additional

Published
2024
Full Text
View/download PDF

9. Evaluation of the Multi-Cancer Early Detection (MCED) value of YiDiXie™-HS and YiDiXie™-SS

Author

Sun, Chen, primary, Lu, Chong, additional, Zhang, Yongjian, additional, Wang, Ling, additional, Ge, Zhenjian, additional, Wen, Zhenyu, additional, Chen, Wenkang, additional, Li, Yingqi, additional, Wu, Yutong, additional, Lin, Shengjie, additional, Zhang, Pengwu, additional, Wang, Wuping, additional, Chen, Siwei, additional, Zhou, Huimei, additional, Li, Xutai, additional, Wang, Shaobin, additional, Xia, Yong, additional, Li, Wei, additional, Lan, Wei, additional, Cai, Yongjiang, additional, Ji, Ling, additional, Wang, Haibo, additional, and Lai, Yongqing, additional

Published
2024
Full Text
View/download PDF

14. The value of a panel of circulating microRNAs in screening prostate cancer

Author

Sun, Chen, primary, Lu, Chong, additional, Li, Xinji, additional, Li, Rongkang, additional, Wen, Zhenyu, additional, Ge, Zhenjian, additional, Chen, Wenkang, additional, Li, Yingqi, additional, Sun, Suolei, additional, Yang, Qingshan, additional, Tao, Lingzhi, additional, Li, Hang, additional, and Lai, Yongqing, additional

Published
2024
Full Text
View/download PDF

16. Testing the accuracy of a four serum microRNA panel for the detection of primary bladder cancer: a discovery and validation study.

Author

Lu, Chong, Lin, Shengjie, Wen, Zhenyu, Sun, Chen, Ge, Zhenjian, Chen, Wenkang, Li, Yingqi, Zhang, Pengwu, Wu, Yutong, Wang, Wuping, Chen, Siwei, Zhou, Huimei, Li, Xutai, Li, Hang, Tao, Lingzhi, Hu, Yimin, Zhao, Zhengping, Chen, Zebo, Wu, Xionghui, and Lai, Yongqing

Subjects
BLADDER cancer, MICRORNA, LOGISTIC regression analysis, GENE expression, TUMOR markers
Abstract

Bladder cancer (BC) is one of the ten most common cancers worldwide with late detection and early age of diagnosis. There is abundant evidence that early detection and timely intervention can lead to a better prognosis of BC. Substantial evidence has indicated that microRNAs (miRNAs) are specific to different tumour types and are remarkably stable, indicating that serum miRNAs may serve as potential cancer diagnostic markers. This study aimed to identify suitable serum miRNAs to create a panel that can be used to diagnose primary BC. In this study, 18 miRNAs that were differentially expressed in BC were obtained from the PubMed or Gene Expression Omnibus database. Then, 18 BC-related-miRNAs were verified in screening and validation sets created using 56 (28 primary BC vs. 28 NCs) and 168 (84 primary BC vs. 84 NCs) serum samples, respectively. Quantitative reverse transcription-PCR (qRT-PCR) was performed to verify the identity of the differential miRNAs. A multi-miRNA panel with superior diagnostic performance was constructed. TCGA and KEGG databases were used to conduct the survival analysis and bioinformatics analysis, respectively. Six serum miRNAs (miR-221-5p, miR-181a-5p, miR-98-5p, miR-15a-5p, miR-222-3p, and miR-197-3p) were significantly aberrantly expressed in the BC patients, while four miRNAs from among them (miR-221-5p, miR-181a-5p, miR-15a-5p, miR-222-3p) were assembled into a panel that showed high diagnostic value (AUC = 0.875, 95% CI: 0.815 − 0.921; sensitivity: 82.14%; and specificity: 85.71%) based on the logistic regression analysis. The survival analysis showed that miR-181a-5p was closely associated with BC prognosis (Log-rank p-value < 0.05). The combination of the four miRNAs (miR-221-5p, miR-181a-5p, miR-15a-5p and miR-222-3p) may be a novel non-invasive serological biomarker for BC screening. Early detection and timely intervention can lead to a better prognosis of bladder cancer. This study aimed to identify suitable serum miRNAs to create a panel that can be used to diagnose primary bladder cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Corrigendum to “MiR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer” [Life Sciences, 209 (2018) 15–23]

Author

Li, Zuwei, primary, Zhou, Liang, additional, Lin, Canbin, additional, Pan, Xiang, additional, Xie, Jiansen, additional, Zhao, Liwen, additional, Quan, Jing, additional, Xu, Jinling, additional, Guan, Xin, additional, Xu, Weijie, additional, Li, Hang, additional, Chen, Yun, additional, and Lai, Yongqing, additional

Published
2023
Full Text
View/download PDF

28. A serum miRNAs signature for early diagnosis of bladder cancer.

Author

Yu, Zuhu, Lu, Chong, and Lai, Yongqing

Subjects
BLADDER cancer, CANCER diagnosis, EARLY diagnosis, MICRORNA, GENE expression, EARLY detection of cancer
Abstract

Bladder cancer accounts for the most common type of urologic malignancy and presents high recurrence rate after surgical resection and adjuvant intravesical therapy. We aim to search for an early diagnostic biomarker in serum for bladder cancer in this study. The expression profiles of miRNAs in serum samples of 112 bladder cancer patients and 112 healthy controls were detected with real-time polymerase chain reaction (RT-qPCR). Receiver operating characteristic (ROC) curve and area under curve (AUC) analysis were performed to assess the diagnostic efficiency of miRNAs. Stepwise logic regression analysis was used to construct a diagnostic signature with highest sensitivity and specificity. Bioinformatics analysis was applied to explore the potential biological functions and mechanisms of candidate miRNAs. Five miRNAs including miR-451a, miR-381-3p, miR-223-3p, miR-142-5p and miR-27b-3p were found differentially expressed in serum samples of bladder patients and healthy subjects. The diagnostic signature was constructed with miR-27b-3p, miR-381-3p and miR-451a. AUC of the three-miRNA signature was 0.894 (0.837–0.936, p < 0.001). The sensitivity and specificity of this signature were 86.90% and 77.38%, respectively, indicating that this signature has a good ability to diagnose bladder cancer. The three-miRNA signature we constructed has favorable diagnostic capacity and may be a promising non-invasive biomarker in the early diagnosis of bladder cancer. There is still no clinical utilization of serum miRNAs in the early detection of bladder cancer. We screened and constructed a three-miRNA signature with the sensitivity of 86.90% and specificity of 77.38% which may be a promising non-invasive biomarker in the early diagnosis of bladder cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. A four-microRNA panel in serum may serve as potential biomarker for renal cell carcinoma diagnosis

Author

Li, Rongkang, primary, Chen, Wenkang, additional, Lu, Chong, additional, Li, Xinji, additional, Chen, Xuan, additional, Huang, Guocheng, additional, Wen, Zhenyu, additional, Li, Hang, additional, Tao, Lingzhi, additional, Hu, Yimin, additional, Zhao, Zhengping, additional, Chen, Zebo, additional, Ni, Liangchao, additional, and Lai, Yongqing, additional

Published
2023
Full Text
View/download PDF

35. The value of a group of serum miRNAs in screening prostate cancer

Author

Sun, Chen, primary, Li, Xinji, additional, Li, Rongkang, additional, Lu, Chong, additional, Wen, Zhenyu, additional, Ge, Zhenjian, additional, Chen, Wenkang, additional, Li, Yingqi, additional, Sun, Suolei, additional, Yang, Qingshan, additional, Tao, Lingzhi, additional, Li, Hang, additional, and lai, yongqing, additional

Published
2022
Full Text
View/download PDF

37. Bladder cancer diagnosis with a four-miRNA panel in serum

Author

Li, Xinji, primary, Chen, Wenkang, additional, Li, Rongkang, additional, Chen, Xuan, additional, Huang, Guocheng, additional, Lu, Chong, additional, Wen, Zhenyu, additional, Peng, Xiqi, additional, Liu, Kaihao, additional, Zhang, Chunduo, additional, Li, Hang, additional, Hu, Yimin, additional, Zhao, Zhengping, additional, Tao, Lingzhi, additional, and Lai, Yongqing, additional

Published
2022
Full Text
View/download PDF

38. A four-miRNA signature in serum as a biomarker for bladder cancer diagnosis

Author

Li, Rongkang, Chen, Xuan, Li, Xinji, Huang, Guocheng, Lu, Chong, Wen, Zhenyu, Chen, Zebo, and Lai, Yongqing

Subjects
Original Article
Abstract

Background: Urinary bladder cancer (BCa) is globally the 10th most frequent cancer. As a novel diagnostic tool, miRNA in serum screening is non-invasive. This project aimed to determine particular serum miRNAs as novel biomarkers for diagnosing urinary BCa. Methods: We designed a three-phase study with 122 healthy controls (HCs) and 132 BCa patients. The 30 miRNAs’ expressions in serum from HCs and BCa patients were detected during the screening phase. The miRNAs with the most dysregulation were tested in the training (HCs vs. BCa, 30 each) and validation (80 HCs vs. 82 BCa) phase further. The diagnostic ability of these candidate miRNAs was estimated by the receiver operating characteristic (ROC) curves as well as the area under the ROC curve (AUC). The miRNAs’ target genes and their annotations to functions were predicted utilizing bioinformatic assays. Results: Six serum miRNAs (miR-124-3p, miR-182-5p, miR-1-3p, miR-196a-5p, miR-23b-3p and miR-34a-5p) had significantly different expression between BCa patients and HCs in the training and validation phase. The four-microRNA panel improved the diagnostic value, with AUC =0.985. The result of bioinformatic analysis showed that these miRNAs’ target genes in the panel may be related to the MAPK signaling pathway in bladder cancer. Conclusions: Our study identified a four-miRNA panel that is a non-invasive new biomarker for diagnosing BCa.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results